Information Provided By: 
Fly News Breaks for April 24, 2019
ZBH
Apr 24, 2019 | 06:39 EDT
Needham analyst Mike Matson upgraded Zimmer Biomet to Strong Buy and raised his price target to $155 from $146, saying the company has addressed supply issues and should "benefits from the launches of its new knee products and Rosa knee and spine/brain robots." The analyst sees the company's revenues accelerating this year while it also pursues acquisitions to boost its organic growth and diversify its products. Matson adds that Zimmer Biomet shares trade at a 34% discount relative to its large-cap med-tech peers.
News For ZBH From the Last 2 Days
There are no results for your query ZBH
